Ketoret

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ketoret

Property Description
Active ingredient Ketoprofen (INN)
Type/Origin Synthetic compound
Pharmacological Class Non-Steroidal Anti-Inflammatory Drug (NSAID)
Primary Forms Tablets, Capsules, Solution for Injection, Topical Gel
General Purpose Symptomatic relief of pain, inflammation, and fever

1. Identity and Pharmaceutical Classification of Ketoprofen

Ketoprofen, the active pharmaceutical ingredient in the entity referenced as Ketoret, is a synthetic compound classified as a potent Non-Steroidal Anti-Inflammatory Drug (NSAID). This classification is clinically recognized for its therapeutic potential in managing symptoms linked to inflammatory responses. Chemically, it belongs to the arylpropionic acid derivative group. Medicines containing ketoprofen are recognized for their anti-inflammatory properties and analgesic efficacy across various formulations. The medicine’s fundamental action is centered on reducing inflammation and pain signals.

2. General Purpose and Triple Therapeutic Action

The general purpose of Ketoprofen is to deliver crucial symptomatic relief via a triple therapeutic action: managing pain, reducing inflammation, and moderating fever. This efficacy is rooted in the inhibition of cyclooxygenase (COX) enzymes, thereby blocking the synthesis of prostaglandins, the endogenous lipid compounds responsible for mediating these key symptoms. As an NSAID, ketoprofen interrupts the physiological processes that lead to elevated pain signals and inflammatory responses. Its distinct pharmacological profile, often noted for a rapid onset of action in certain oral forms, makes it a specialized option in acute symptomatic scenarios.

3. Available Pharmaceutical Forms and Composition

Ketoprofen is available in various pharmaceutical preparations to ensure flexibility in its route of administration. These preparations include solid forms like tablets and capsules for oral use, and specialized preparations such as solutions for injection (parenteral) and topical preparations (gels or dermal patches). The composition of each form features the active ingredient, Ketoprofen, combined with necessary bases or vehicles appropriate for the intended delivery route, ensuring the medicine’s stability and effective absorption whether administered orally, topically, or parenterally. The development of dermal patches highlights a specialized form intended for localized symptomatic application, distinguishing it from the systemic delivery of standard oral NSAID forms.

Regulatory References

  1. National Library of Medicine's (NLM) MedlinePlus on Ketoprofen

What side effects are possible with Ketoret?

Possible Side Effects and Safety Information

Note on Regulatory Data for Ketoret

The most authoritative information regarding the side effects, safety profile, and usage restrictions for any medicinal product is found in the official regulatory documents published by government bodies such as the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA). These documents define the clinically significant adverse reactions and mandated safety monitoring for patient protection.

Specific, publicly available regulatory documentation detailing the adverse reactions, frequency classifications, or official safety restrictions for a pharmaceutical product named Ketoret is currently not identifiable in major global governmental regulatory databases.


Regulatory Safety Structure (Framework)

In the regulatory context, a complete safety profile, if available, would detail adverse drug reactions (ADRs) according to formal classifications:

  • Frequency Classification: Reactions are grouped by how often they occur (e.g., very common, common, rare, very rare) based on clinical trial data, following frameworks like the ICH classification bands.
  • System-Organ Classes (SOCs): ADRs are organized by the affected body system (e.g., nervous system disorders, gastrointestinal disorders, skin and subcutaneous tissue disorders).
  • Serious Adverse Reactions: These are events that require hospitalization, result in death, are life-threatening, or result in persistent or significant disability, and are highlighted in regulatory labeling.

Safety Restrictions and Monitoring

Official regulatory documents typically include mandatory safety-related restrictions, such as contraindications (situations where the drug must not be used), warnings concerning particular patient populations (e.g., those with severe liver or kidney impairment), and the need for specific laboratory monitoring. Without a confirmed, publicly available regulatory label for Ketoret, these essential details cannot be specified here. Patients should always consult the official labeling or a healthcare professional for the most current safety information concerning their medication.

Overdose and Emergency Response

Overdose and When to Seek Help (Official Regulatory Information)

The official regulatory profile for Ketoprofen (Ketoret) classifies an overdose as an event with the potential for serious and life-threatening outcomes, necessitating immediate professional medical intervention.

Documented Manifestations and Severe Outcomes

Manifestations documented in regulatory sources primarily involve the gastrointestinal and central nervous systems. Symptoms include nausea, vomiting, stomach pain, drowsiness, and confusion. Severe complications are officially noted to include acute renal failure, major gastrointestinal bleeding, seizures, and coma. The cardiovascular and respiratory systems may also be affected, leading to difficulty breathing or blood pressure fluctuations.

Emergency Actions Mandated by Regulators

It is explicitly mandated in official labeling that individuals must seek immediate medical help right away upon suspicion of overdose. This requires immediate contact with emergency services and transfer for hospital monitoring.

No specific antidote is known for Ketoprofen. Consequently, management described in regulatory documents is focused on providing symptomatic and supportive treatment. This includes monitoring of vital signs (e.g., blood pressure, heart rate) and clinical procedures such as activated charcoal administration or gastric lavage to remove unabsorbed medicine, where appropriate. Official documentation also notes that individuals with pre-existing renal or cardiac impairment are at an increased risk for severe organ toxicity following an acute overdose.

Therapeutic Uses of Ketoret

What Ketoret Treats: Main Uses and Benefits

Ketoprofen (Ketoret) is commonly used for managing symptoms related to physical discomfort, such as pain, inflammation, and fever. Its application is generally considered relevant in clinical settings marked by heightened patient distress or when supportive symptom management is appropriate.


Key Therapeutic Domains

This medication is applied across therapeutic domains involving inflammatory or irritative states. It helps address symptom clusters that may become intense or disruptive in conditions like Rheumatoid Arthritis, Osteoarthritis, Ankylosing Spondylitis, and acute gouty arthritis. It is also commonly used for managing symptoms related to surgical procedures (including dental surgery), pain from sprains and strains, and intense, episodic discomfort such as renal colic and primary dysmenorrhoea.

Quick Fact: Relief for Pain and Swelling The medicine is commonly used to help with symptomatic relief in conditions where pain and swelling cluster together, such as acute joint flare-ups or soft tissue trauma, which may assist with maintaining comfort and easing functional strain.


Patient Benefit and Context of Use

Ketoprofen is often used during phases when symptoms become more noticeable, providing support that helps ease the overall symptom burden. It assists with maintaining functional stability and offers symptomatic relief that helps patients cope more steadily with difficult episodes. It is generally applied in scenarios where additional management of discomfort is required, supporting general well-being during symptomatic phases. It is also relevant for easing symptoms that interfere with daily functioning.

Regulatory References

  1. MedlinePlus Drug Information

Eligibility and Restrictions for Use

Official Eligibility Profile for Ketoprofen (Ketoret) Use

Eligibility to use Ketoprofen is defined by specific regulatory criteria across four core domains: absolute contraindications, organ function status, age, and reproductive condition. These rules ensure that use remains strictly within established regulatory boundaries.

Contraindicated Populations (Must Not Use)

Category Regulatory Statement
Hypersensitivity/Allergy Known allergy to ketoprofen, or history of asthma, urticaria, or allergic reactions induced by aspirin or other NSAIDs.
Severe Organ Failure Patients with active peptic ulceration or history of GI bleeding, or those with severe heart, renal, or hepatic insufficiency.
Cardiovascular/Pregnancy Use in the setting of Coronary Artery Bypass Graft (CABG) surgery, or during the third trimester of pregnancy (after 30 weeks).

Age and Condition Restrictions

Category Regulatory Status
Pediatrics Safety and effectiveness have not been established for prescription use in patients under 18 years.
Older Adults Conditional use; requires caution, lower initial dosing, and close monitoring due to increased risk of adverse effects.
Lactation Not recommended or advised to be avoided due to the possibility of excretion into breast milk.

This structure reflects how official regulatory bodies define which populations are eligible, which are restricted, and which are absolutely prohibited from using Ketoprofen.

What should I know about interactions with other medicines?

The official interaction profile for Ketoprofen (Ketoret) details specific combinations and conditions that carry a heightened risk, as documented in government regulatory sources.

Regulatory Interaction Restrictions

Classification Interacting Agents or Conditions
Formally Contraindicated Other NSAIDs or high-dose Salicylates (e.g., Aspirin); Peri-operative pain in the setting of CABG surgery.
Exposure Modification Lithium and Methotrexate (reduced renal clearance of these agents).
Pharmacodynamic Risk Oral Anticoagulants (e.g., Warfarin), Heparin, Corticosteroids, and Anti-platelet Agents (increased risk of bleeding/hemorrhage).
Effect Reduction Diuretics, ACE Inhibitors, and Angiotensin-II Antagonists (diminished antihypertensive/diuretic efficacy; increased risk of renal effects).

Other Documented Interactions

Regulatory information notes that co-administration with food does not change the total exposure of Ketoprofen but slows the rate of absorption. Interactions with alcohol and certain herbal products (like Ginger, Garlic, Ginkgo) are documented to increase the potential for gastrointestinal or bleeding-related adverse effects. Elderly patients are identified in regulatory labeling as being at a greater risk for serious gastrointestinal events and susceptibility to renal effects, especially when combined with drugs like diuretics or ACE inhibitors.

Mechanism of Action

Targeted Inhibition of the Eicosanoid Cascade

Ketoprofen's primary action involves reversible non-selective inhibition of the Cyclooxygenase (COX) enzymes, targeting both the constitutive COX-1 and inducible COX-2 isoforms. This molecular interaction suppresses the synthesis of signaling molecules, specifically prostaglandins, that modulate physiological responses. The core mechanistic sequence involves the inhibition of the COX enzyme ightarrow reduced prostaglandin synthesis ightarrow modulation of mediator activity on cellular function.

Modulation of Central and Peripheral Signaling

The mechanism operates across different physiological systems, encompassing dual central and peripheral effects. In the periphery, the drug limits prostaglandin-mediated sensitization of nociceptors (pain-sensing nerve endings). Centrally, its action in the hypothalamus alters an elevated thermoregulatory set-point. This dual modulation is key to regulating prostaglandin-mediated signaling within nociceptive and central thermoregulatory pathways.

Secondary Cellular and Pathway Contributions

Beyond the primary COX inhibition, the mechanism involves complementary actions, including the potential modulation of the Lipoxygenase (LOX) pathway and the stabilization of lysosomal membranes within inflammatory cells. These secondary contributions affect the release of hydrolytic enzymes and influence the inflammatory cascade, shaping the overall physiological effect profile.

Dosage and Administration Information

Ketoprofen (Ketoret) is administered through multiple approved routes, including Oral (tablets or capsules), Topical (gel), and Parenteral (injection), establishing either a systemic or localized therapeutic approach. The required dosing schedule is dependent on the formulation's release profile. Immediate-release oral forms typically require administration three to four times daily (q6-8hr) to maintain systemic levels, while extended-release capsules are officially dosed once daily (QD).

For acute symptom relief, the immediate-release form may be used as needed in 25 mg to 50 mg increments, up to a standard maximum daily dose of 300 mg. Use for acute symptoms, such as pain or fever, is generally limited to 10 days. Oral forms may be taken with food, milk, or antacids to minimize potential gastrointestinal upset. A crucial special handling requirement is that extended-release preparations must be swallowed whole and must not be crushed or chewed, as this alters the drug's intended release.

The topical gel is intended for localized application and is typically massaged into the affected area two to four times daily, with use for localized soft tissue pain generally limited to 7 days.

Population-specific adjustments are an official principle of administration. For older adults and patients with renal or hepatic impairment, clinical principles involve the use of lower initial doses and reduced maximum daily limits (e.g., 100 mg/day maximum in severe hepatic dysfunction). If a dose of the immediate-release form is missed, the recommended procedure is to skip the missed dose and resume the regular schedule, avoiding a double dose.

Recent Clinical Evidence

Research evidence / Overview of Studies for Ketoret (Ketoprofen)


Evidence for Symptomatic Management of Chronic Inflammatory Conditions

Research exploring Ketoprofen's use for chronic inflammatory conditions, such as Rheumatoid Arthritis and Osteoarthritis, has primarily relied on Randomized Controlled Trials (RCTs) and subsequent Systematic Reviews. These studies were used in research exploring how symptoms change over time in adults whose conditions are characterized by fluctuating or episodic manifestations. The research explored which outcomes related to physical discomfort, such as pain intensity, and outcomes reflecting daily functioning, like joint mobility and stiffness, were measured in the study. The evidence derived from these trials describes symptoms monitored over short time intervals.

What remains uncertain is the research context beyond this symptomatic monitoring. There is limited information for long-term outcomes regarding the evidence base's influence on the overall progression of the condition or any potential impact on joint structure. Comparative evidence is sometimes lacking against other newer therapeutic options.


Evidence for Use in Acute Pain and Short-Term Conditions

RCTs were applied in this context, including single-dose and short-course studies, which examined outcomes related to acute, temporary pain. This includes conditions associated with acute or disruptive episodes, such as musculoskeletal strains, post-operative discomfort, and intense primary dysmenorrhoea. Research focused on outcomes describing episodic or acute changes. Studies conducted during periods of increased symptom activity monitored whether outcomes related to physical discomfort showed patterns after administration over defined time intervals. These findings contribute to the body of evidence describing how patients reported their experience during acute episodes.

However, the follow-up durations were limited, meaning the evidence derived from settings with varying symptom burdens is highly focused on acute symptomatic changes. Research is insufficient for conditions that involve temporary physiological imbalance but require management beyond a few days.


Research on Topical Versus Systemic Administration

Studies have explored the differences between using Ketoprofen in its oral form (systemic administration) and in its topical forms (such as gels or patches for localized application). These trials were applied in research contexts involving fluctuating or unstable symptoms localized to an area, such as a joint or soft tissue injury. The research focused on outcomes related to physical discomfort at the site of application and the absorption rate of the medicine into the bloodstream. Studies monitored the topical forms and reported measurements of local pain scores. The medicine was observed in studies examining symptom intensity or variability locally.

What remains uncertain is the consistency of the localized effect across all types of topical formulations, as results appear to be influenced by the specifics of the drug delivery system. Comparative evidence is also lacking in head-to-head trials against the oral form for a broad range of localized conditions.


Evidence in Specific Patient Populations and Research Gaps

Research has explored the use of Ketoprofen in various subgroups. For older adults, studies were applied in research contexts involving chronic pain and outcomes related to functional limitations. Studies have also been conducted in children and adolescents for acute, temporary conditions. Findings describe patterns observed in these populations, which contribute to the broader evidence landscape describing how symptoms are measured in this age group.

Data for certain groups remain insufficient. Long-term effects are not fully established for the older adult population. Furthermore, sample sizes were modest in studies involving children and adolescents, meaning evidence quality varies across studies. Comparative evidence is lacking in many areas; research exploring short-term symptom changes has not fully established the outcomes for patients with certain comorbid conditions. Data are still emerging for some specialized formulations, and research outcomes were sometimes inconsistent.

Key Studies & References Ketoprofen (MedlinePlus Drug Information - Main Uses and Benefits Overview)

Frequently Asked Questions (FAQ)

Common questions about Ketoret (FAQ)


Q: Does Ketoret work immediately, or does it take time to build up in the system?

Official regulatory studies for the immediate-release oral form of Ketoret indicate that it is rapidly absorbed. Some patients may begin to report relief from symptoms within approximately 30 minutes after taking a single dose. Consistent drug levels, known as steady-state concentrations, are usually reached within 24 hours of starting regular treatment.


Q: Can Ketoret be taken at the same time as common over-the-counter pain relievers?

Regulatory documents formally advise against taking Ketoret concurrently with other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) or high-dose salicylates, such as aspirin. This combination is avoided because it significantly increases the risk of serious side effects on the digestive system. The regulatory documents primarily detail risks associated with other NSAIDs and high-dose salicylates, and do not specifically comment on every non-NSAID pain reliever like acetaminophen in the contraindications.


Q: Does taking Ketoret require any specific changes to my diet or what I drink?

Official product information notes that taking the oral form of Ketoret with food, milk, or antacids can help minimize the potential for stomach upset. Although food can slow down the speed at which the medicine is absorbed, it does not change the total amount the body receives. Regulatory documents specifically advise against consuming alcohol while taking Ketoret, as this may increase the potential for gastrointestinal bleeding.


Q: Is Ketoret safe for long-term use, according to official research?

Regulatory warnings for medications in this class, including Ketoret, caution that their use may increase the risk of serious cardiovascular events, such as heart attack or stroke. Regulatory guidance suggests that, to help mitigate potential risks, the medicine should be used at the lowest effective dose for the shortest duration necessary, according to official documents.


Q: What kind of monitoring or regular tests are usually recommended while on Ketoret?

Official regulatory guidance recommends that a patient's blood pressure be monitored closely when starting treatment with Ketoret and throughout the course of therapy. The possibility of effects on the liver means that regulatory documents highlight the potential for patients to experience elevations in liver enzyme tests, and symptoms suggesting liver dysfunction may prompt clinical evaluation.


Q: Are generic versions of Ketoret considered just as effective as the brand name?

Major regulatory bodies, such as the US FDA, require that generic versions of a prescription medicine be bioequivalent to the brand-name product. This means the generic product contains the same active ingredient and is required to demonstrate it works in the body within the same accepted range and time frame as the branded medicine.


Q: Is it possible for Ketoret to interact with herbal supplements like St. John's Wort or Ginkgo Biloba?

Official documents note that certain herbal products, including Ginkgo, may increase the potential for bleeding or gastrointestinal side effects when taken with Ketoret. The official label suggests that patients provide their healthcare professional with a list of all herbal products and supplements being taken.


Q: Is there a maximum time frame for how long a patient can be on Ketoret?

Regulatory guidance specifies that the use of Ketoret for the treatment of acute symptoms (such as pain or fever) is limited to a maximum of 10 days. For chronic conditions, regulatory recommendations prioritize using the lowest effective dose for the shortest duration to reduce the risk of potential long-term adverse events.


Q: Does Ketoret interact with common foods or specific types of juice?

Regulatory documents confirm that taking Ketoret with food does not change the total exposure the body receives but does slow the speed of absorption. The core regulatory label typically does not contain specific warnings or known interactions with common fruit juices.


Q: If I have an allergy to another medication, am I more likely to be allergic to Ketoret?

Official regulatory information states that Ketoret is absolutely contraindicated if you have a known allergy to the medicine itself. Furthermore, it must not be used by patients who have a history of allergic reactions, asthma, or hives that were caused by aspirin or any other Non-Steroidal Anti-Inflammatory Drug (NSAID).


Q: Can Ketoret be taken with other medications that cause drowsiness?

Regulatory documentation lists side effects such as drowsiness (somnolence) and dizziness as possible events associated with Ketoret use. Because regulatory documentation notes drowsiness as a possible side effect of Ketoret, co-administration with other medicines causing central nervous system (CNS) effects may be associated with an increased potential for additive drowsiness.


Q: Is it normal to feel nauseous or have stomach discomfort when first starting Ketoret?

Gastrointestinal issues, including nausea, upset stomach, and constipation, are commonly reported side effects listed in official patient information. Patients are sometimes advised to take the medicine with food or milk to help minimize these possible digestive effects.


Q: How does Ketoret's 'half-life' relate to how often I need to take it?

The official label notes that Ketoret has a short elimination half-life—the time it takes for the amount of medicine in the body to be reduced by half—of approximately 2.1 to 2.5 hours. This short duration requires that immediate-release forms be taken multiple times a day to maintain steady therapeutic levels.


Q: Does Ketoret affect fertility in men or women?

Official regulatory advisories indicate that Ketoret, being an NSAID, may potentially impair female fertility and is not typically recommended for women who are actively trying to conceive. No specific regulatory warnings regarding effects on male fertility are detailed in the core human product label.


Q: What are the specific warnings about Ketoret use in patients with a history of seizures?

The regulatory label documents adverse effects that can occur on the nervous system. While a history of seizures is not listed as an absolute contraindication, regulatory listings do mention convulsions (seizures) as a rare possible adverse event.


Q: Can Ketoret cause mental changes, like mood swings or anxiety?

Some regulatory documentation includes serious but rare side effects such as mental or mood changes and nervousness. Some external research also discusses a possible association between Ketoprofen and changes in mood reporting, though this is not a core warning.


Q: Does Ketoret cause weight gain or weight loss?

Official documents list unexplained weight gain as a serious potential side effect, which may be related to fluid retention or edema (swelling), known to occur with NSAID use. Weight loss is sometimes listed as a less frequent adverse reaction in clinical databases.


Q: What happens if I accidentally miss a dose of Ketoret?

Official administration instructions for the immediate-release oral form state that if a dose is missed, the protocol is to skip that missed dose entirely. The recommended procedure is to then resume the regular schedule and avoid taking a double dose to compensate for the skipped one. Instructions for other forms may differ.


Q: Is it a problem if I take Ketoret a couple of hours later than usual?

Regulatory instructions for missed doses do not specify a precise acceptable delay window for a dose. The general rule for the immediate-release form is to skip the dose if it is close to the next scheduled time. The core principle is to avoid doubling up on the dose.


Q: Can Ketoret be used by people with a history of liver or kidney problems?

Official documentation contraindicates (prohibits) the use of Ketoret in patients with severe heart, renal, or hepatic insufficiency. Regulatory guidance also specifies that patients with less severe liver or kidney impairment, or older adults, must be managed using lower initial doses and reduced maximum daily limits.


Q: Does Ketoret affect or interact with birth control pills?

The official interaction profile lists numerous drug combinations with heightened risk, but it does not specifically mention oral contraceptives or hormonal birth control. Patients should report the use of any hormonal medication to their healthcare professional for evaluation.


Q: Are there any documented cases of Ketoret withdrawal symptoms if stopped suddenly?

Regulatory documentation for Ketoprofen, which is classified as an NSAID, does not contain specific warnings or statements regarding dependence or formal withdrawal symptoms if the medicine is stopped suddenly. The product is not listed as a controlled substance.


Q: What is the official information regarding crushing, splitting, or chewing Ketoret tablets?

Official special handling requirements strictly mandate that extended-release preparations must be swallowed whole and must not be crushed, split, or chewed. This is required because altering the tablet changes the way the drug is released into the body. Guidance for non-extended-release forms is not explicitly stated in the core regulatory texts.


Q: Are there any known long-term effects of Ketoret use that I should be aware of?

Research and regulatory documents caution that the use of NSAIDs is associated with long-term risks, particularly regarding serious cardiovascular events and the potential for gastrointestinal bleeding. For older adults, research has noted limitations in long-term safety data, emphasizing the need to use the lowest effective dose for the shortest duration.


Q: What is the evidence for Ketoret use in the pediatric population?

The official eligibility profile states that safety and effectiveness for prescription use of Ketoret have not been established for patients under 18 years of age. Research has been conducted in children and adolescents for acute, temporary conditions, but official reports note that these studies had modest sample sizes and evidence quality varies.

How should Ketoret be stored and disposed of?

How to Store and Dispose of Ketoprofen (Ketoret) — Official Regulatory Information

Labeled storage temperature requirements: Store at Controlled Room Temperature, typically 20 C to 25 C.
Light/moisture protection requirements: Must be protected from light and excessive moisture (humidity).
Handling requirements: Do not freeze the product (especially liquid or gel formulations).
Packaging-related storage rules: Keep the medicine in its original container and ensure the container is tightly closed.
Child-protection storage requirements: Keep this medicine out of the sight and reach of children.
Official disposal instructions: Do not dispose of unused or expired medicine via wastewater or household waste (trash).

Regulatory documents define how the product must be stored and protected by mandating specific temperature ranges and requiring protection from light and moisture. Storage in the original, tightly closed container is required to maintain stability. Disposal is strictly defined by government instruction, which requires the return of unused product to an authorized collection point rather than disposal in household waste or sewage systems. Specific post-opening stability limits may apply to certain topical forms.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ketoret found in:

A-Z Index: